Otsuka Pharmaceutical Co Ltd v. MSN Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Defendant: MSN Pharmaceuticals Inc. (Delaware) and MSN Laboratories Private Limited (India)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:26-cv-00496, D. Del., 04/30/2026
• Venue Allegations: Venue is alleged as proper in the District of Delaware because Defendant MSN Pharmaceuticals Inc. is a Delaware corporation and Defendant MSN Laboratories Private Limited is a foreign corporation.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) for generic tolvaptan tablets constitutes an act of infringement of three U.S. patents related to the drug's composition, formulation, and manufacturing processes.
• Technical Context: The technology concerns the pharmaceutical compound tolvaptan, marketed as JYNARQUE®, which is used to slow kidney function decline in adults with autosomal dominant polycystic kidney disease (ADPKD).
• Key Procedural History: This action was initiated under the Hatch-Waxman Act following Defendants' submission of ANDA No. 219581 with a Paragraph IV certification, asserting that Plaintiff's patents are invalid, unenforceable, or will not be infringed by the proposed generic product. The complaint was filed within 45 days of Plaintiff's receipt of Defendants' notice letter, triggering a statutory 30-month stay on FDA approval of the ANDA. The patents-in-suit are listed in the FDA's "Approved Drug Products with Therapeutic Equivalents" (the Orange Book) for JYNARQUE®.

Case Timeline

Date	Event
2005-09-02	Priority Date for '730 Patent and '735 Patent
2007-06-21	Priority Date for '694 Patent
2012-09-25	'735 Patent Issued
2013-08-06	'730 Patent Issued
2018-04-23	FDA Approved Otsuka's New Drug Application (NDA) for JYNARQUE®
2021-02-02	'694 Patent Issued
2026-03-19	Otsuka Received "Notice of Paragraph IV Certification" Letter from MSN
2026-04-30	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,501,730 - "`Process for Preparing Benzazepine Compounds or Salts Thereof`" (issued August 6, 2013)

The Invention Explained

• Problem Addressed: The patent, which is a continuation of the application leading to the '735 patent, identifies a need for an improved industrial-scale manufacturing process for certain benzazepine compounds Compl. ¶1 '735 Patent, col. 2:50-59 Prior methods were described as not suitable for producing the desired compounds in high yield and with high purity on an industrial scale '735 Patent, col. 2:50-59
• The Patented Solution: The invention claims the active pharmaceutical ingredient (API) tolvaptan itself, but as defined by a specific manufacturing process and purity level. The process involves the reduction of a benzazepine ketone precursor (formula 1) using a specific amount of a hydrogenating agent to create the final hydroxyl-containing compound (formula 10) '730 Patent, col. 12:40-67 This method is asserted to produce a "highly pure" final product '730 Patent, col. 29:10-14
• Technical Importance: This process enables the efficient, large-scale synthesis of the pharmaceutically active compound tolvaptan, which is critical for commercial drug manufacturing '730 Patent, col. 20:45-51

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶37 Compl. ¶39
• Essential elements of Claim 1 include:
  • A highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine having a purity of more than 99.5%, or a salt thereof;
  • which is produced by a process comprising reducing a specific benzazepine precursor compound (formula 1);
  • in the presence of a hydrogenating agent selected from a specific group (lithium aluminum hydride, sodium borohydride, etc.);
  • wherein the agent is used in an amount of 0.25 to 1 mole per 1 mole of the precursor compound.

U.S. Patent No. 10,905,694 - "`Pharmaceutical Solid Preparation Comprising Benzazepines and Production Method Thereof`" (issued February 2, 2021)

The Invention Explained

• Problem Addressed: The patent's background describes that while the tolvaptan API has excellent pharmacological activity, its poor solubility leads to insufficient absorption in the gastrointestinal tract '694 Patent, col. 1:26-31 A prior art attempt to improve solubility by creating an amorphous composite with hydroxypropylcellulose (HPC) was unsuccessful because tablets made from it failed to disintegrate properly '694 Patent, col. 1:35-44
• The Patented Solution: The invention discloses a specific pharmaceutical formulation that combines the amorphous tolvaptan-HPC composite with a particular disintegrant: "low substituted hydroxypropylcellulose" (LSHPC) that has a defined average particle diameter and particle size distribution '694 Patent, col. 1:56-2:10 The claimed invention is a solid preparation produced by a multi-step method involving granulation and mixing of these specific components '694 Patent, col. 25:18-26:12
• Technical Importance: This formulation technology provides a solution to the dual challenges of poor API solubility and poor tablet disintegration, enabling the creation of an effective oral solid dosage form with consistent drug release and pharmacological activity '694 Patent, col. 15:10-15

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶47 Compl. ¶49
• Essential elements of Claim 1, a product-by-process claim, include:
  • A pharmaceutical solid preparation obtained by a method comprising several steps:
  • Step 1: Producing amorphous composites of tolvaptan and hydroxypropylcellulose.
  • Step A: Processing a mixture of the amorphous composites, crystalline cellulose, and corn starch/lactose into granules.
  • Step 2: Mixing the granules with low substituted hydroxypropylcellulose having a specified hydroxy propoxyl content, average particle diameter (45 to 65 µm), and 90% cumulative particle diameter (150 to 200 µm).
  • Step 3: Processing the resulting mixture into a solid preparation.

U.S. Patent No. 8,273,735 - "`Process for Preparing Benzazepine Compounds or Salts Thereof`" (issued September 25, 2012)

Technology Synopsis

The patent addresses the need for an industrial-scale process for producing benzazepine compounds with high yield and purity '735 Patent, col. 3:25-32 The patented solution involves specific chemical synthesis pathways, including a process for creating a key intermediate (a benzoic acid compound) and a process for reacting a benzazepine precursor with an amide in the presence of a carbonylating agent to form a benzazepine ketone '735 Patent, col. 4:56-6:11 '735 Patent, col. 6:61-11:2

Asserted Claims

The complaint seeks a declaratory judgment of infringement of claims 6-8 and 10 Compl. ¶56

Accused Features

The complaint alleges that the importation, use, or sale of MSN's ANDA products would infringe these process claims because the products are made by a process patented by the '735 patent Compl. ¶¶54-56

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Defendants' proposed generic tolvaptan tablets in 15, 30, 45, 60, and 90 mg dosage forms, for which Defendants seek FDA approval via ANDA No. 219581 Compl. ¶2 Compl. ¶28

Functionality and Market Context

The accused products are intended to be generic versions of Otsuka's JYNARQUE® tablets Compl. ¶28 The complaint alleges that in their ANDA, Defendants have represented to the FDA that their products are "pharmaceutically and therapeutically equivalent" to JYNARQUE® Compl. ¶35 Compl. ¶45 JYNARQUE® is a prescription drug used to slow the decline of kidney function in adult patients with ADPKD Compl. ¶15

No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

The complaint does not contain detailed infringement contentions or claim charts, as is typical for initial pleadings in ANDA litigation filed before the marketing of the accused product. The infringement theory is based on the allegation that for Defendants' product to be "pharmaceutically and therapeutically equivalent" to JYNARQUE®, it must necessarily practice the asserted claims covering the API, its method of manufacture, and its final formulation Compl. ¶35 Compl. ¶45

'8,501,730 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A highly pure 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine...or a salt thereof	The complaint alleges on information and belief that MSN's ANDA Products contain the tolvaptan active pharmaceutical ingredient and are therapeutically equivalent to JYNARQUE®, thereby meeting this limitation Compl. ¶35	¶35; ¶37	col. 11:27-36
...having a purity of more than 99.5%...	The allegation of therapeutic equivalence suggests that MSN's API must meet the high purity level required by the claim Compl. ¶35 The specific purity of MSN's API is a factual matter for discovery.	¶35; ¶37	col. 29:10-14
...which is produced by the process which comprises reducing a benzazepine compound of the formula (1)...in the presence of a hydrogenating agent...in an amount of 0.25 to 1 mole per 1 mole of the compound (1).	The complaint alleges on information and belief that the submission of the ANDA itself infringes this product-by-process claim Compl. ¶37 Whether MSN's actual manufacturing process for its API falls within the scope of these process limitations is a central factual question for the litigation.	¶37	col. 12:40-67

'10,905,694 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A pharmaceutical solid preparation obtained by a method, comprising: Step 1 of producing amorphous composites consisting of (a) 7-chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzoazepine and/or salt thereof, and (b) hydroxypropylcellulose...	The allegation of therapeutic equivalence suggests that MSN's ANDA Products are solid tablets manufactured via a process that includes creating an amorphous composite of the API and hydroxypropylcellulose Compl. ¶45	¶45; ¶47	col. 7:10-21
...Step A of processing a mixture of (i) the amorphous composites..., (ii) crystalline cellulose, and (iii) corn starch and/or lactose into granules using a granulation method;	The complaint alleges on information and belief that MSN's manufacturing process for its tablets infringes the claimed method Compl. ¶47 This implies the process involves a granulation step with these excipients.	¶47	col. 9:36-41
...Step 2 of mixing the granules obtained in Step A with (c-1) low substituted hydroxypropylcellulose... wherein the low substituted hydroxypropylcellulose... has an average particle diameter of 45 to 65 µm, and has a 90% cumulative particle diameter of 150 to 200 µm...	The allegation of infringement suggests that MSN's formulation process involves mixing the granules with a disintegrant that meets these specific material and particle-size characteristics Compl. ¶47	¶47	col. 7:1-9
...Step 3 of processing the mixture obtained in Step 2 into a solid preparation...	MSN's ANDA Products are tablets, which are a "solid preparation" Compl. ¶2 The complaint alleges the process for making them infringes the claimed method Compl. ¶47	¶47	col. 11:11-23

• Identified Points of Contention:
  • Process vs. Product: For the '730, '735, and '694 patents, a primary point of contention will be factual: do the proprietary manufacturing processes used by Defendants for their API and final drug product actually fall within the scope of the processes recited in the asserted claims? Defendants will likely argue their process is different, constituting a "design around."
  • Scope Questions: For the '694 patent, a key dispute may center on the physical properties of the "low substituted hydroxypropylcellulose" used by Defendants. The analysis will question whether Defendants' excipient meets the precise particle diameter and distribution ranges required by claim 1.

V. Key Claim Terms for Construction

The Term: "highly pure... having a purity of more than 99.5%" ('730 Patent, Claim 1)

• Context and Importance: This term defines a critical quality attribute of the claimed API. Infringement requires Defendants' API to meet this specific purity threshold. Practitioners may focus on this term because the method of measurement (e.g., which impurities are included/excluded, the specific analytical technique) can be outcome-determinative.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim language itself sets a clear numerical floor ("more than 99.5%"). A party might argue any standard, accepted method of purity analysis (like HPLC) showing a result above this floor is sufficient. The patent does not appear to limit the method of measurement in the claims.
  • Evidence for a Narrower Interpretation: The specification provides an example where purity is measured by HPLC under specific conditions, and notes the presence of certain related-substance impurities '730 Patent, col. 24:20-33 '730 Patent, col. 25:35-43 A party could argue that "purity" should be defined in the context of these specific impurities and analytical methods disclosed in the patent.

The Term: "low substituted hydroxypropylcellulose... has an average particle diameter of 45 to 65 µm, and has a 90% cumulative particle diameter of 150 to 200 µm" ('694 Patent, Claim 1)

• Context and Importance: This term provides precise, quantitative parameters for a key excipient. Non-infringement is a possibility if Defendants' chosen excipient falls outside these ranges. Practitioners may focus on this term as a clear potential basis for a non-infringement defense based on designing around the patent.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: A party could argue that the term should cover any LSHPC that functions as a disintegrant and falls within the specified ranges, regardless of its commercial name or supplier, as the patent lists an exemplary product ("LH-11") but claims the physical properties themselves '694 Patent, col. 16:1-6
  • Evidence for a Narrower Interpretation: The specification discloses a specific method for measurement: "a dry method using a laser diffraction type particle size distribution analyzer" '694 Patent, col. 7:13-16 A party could argue that the claim terms must be construed as being measured by this specific technique, and that other measurement methods yielding different results are not relevant to the infringement analysis.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Defendants will actively induce infringement by others (e.g., doctors, patients) and contribute to infringement by selling their ANDA products for use in an infringing manner Compl. ¶39 Compl. ¶49 This is a standard allegation in ANDA litigation, anticipating post-launch activities.
• Willful Infringement: The complaint alleges that Defendants have "actual knowledge" of the patents-in-suit, citing the patents' listing in the Orange Book and Defendants' own Paragraph IV notice letter Compl. ¶30 Compl. ¶36 Compl. ¶46 This forms the basis for a potential claim of willful infringement for any post-launch sales and supports the request for a finding that the case is "exceptional" under 35 U.S.C. § 285 Compl. prayer H

VII. Analyst's Conclusion: Key Questions for the Case

• A primary issue will be a factual one of process infringement: Will discovery reveal that the proprietary manufacturing processes used by MSN for its tolvaptan API and formulated drug product are the same as or equivalent to the specific multi-step processes recited in the asserted claims of the '730, '694, and '735 patents, or did MSN successfully "design around" them?
• A key question for the '694 patent will be one of literal scope: Does the "low substituted hydroxypropylcellulose" excipient used in MSN's formulation meet the precise numerical ranges for particle size distribution required by claim 1, or will the infringement analysis depend on the doctrine of equivalents?
• A foundational issue for the entire litigation will be validity: As Defendants have filed a Paragraph IV certification, the court will have to determine whether the asserted claims of the patents-in-suit are valid and enforceable in light of the prior art and other invalidity defenses that Defendants will raise during litigation.